100 Billion Won Investment and Digital Healthcare Collaboration
Pursuing AI-Based "Connected Healthcare Services"
LG CNS is set to accelerate its digital healthcare business in partnership with Cha Bio Group. The company will invest in Cha Biotech, the holding company of Cha Bio Group, and embark on building artificial intelligence (AI)-based digital healthcare services and platforms.
Hyun Shinkyun, CEO of LG CNS (right), and Cha Wontae, Vice Chairman of Cha Bio Group, are taking a commemorative photo at the strategic partnership agreement ceremony for equity investment and AX·DX business cooperation held on the 14th. Provided by LG CNS
On January 15, LG CNS announced that it had signed a strategic partnership agreement with Cha Biotech on the previous day at the Cha Bio Complex in Pangyo, Seongnam, Gyeonggi Province. The agreement covers an equity investment of 10 billion won and cooperation for AI transformation and digital transformation (AX·DX) business. The signing ceremony was attended by Hyun Shinkyun, CEO of LG CNS, Cha Wontae, Vice Chairman of Cha Bio Group, and other key executives from both companies.
Cha Bio Group is a comprehensive bio and healthcare group encompassing hospitals, pharmaceuticals, bio research, and medical services. Centered around Cha Biotech, the group includes subsidiaries such as Cha AI Healthcare, CMG Pharmaceutical, Cha Vaccine Institute, Cha Healthcare, and Cha Meditech. The group operates hospitals and medical businesses not only in Korea but also overseas, including the United States, Singapore, Australia, and Japan.
Through this investment, LG CNS will form a regular consultative body with Cha Bio Group to carry out major AX·DX projects. In the short term, the companies will promote the transition of the group's cloud infrastructure and build a smart big data platform to integrate data. They will also upgrade therapeutic production facility infrastructure with AI technology to optimize production processes.
In the mid-to-long term, the two companies will jointly commercialize "Connected Healthcare Services," a strategic business of Cha Bio Group based on specialized AI models. This service analyzes a wide range of health and lifestyle data generated from hospitals, residential spaces, and wearable devices using healthcare-specific AI. When health risk signals are detected, the system automatically links follow-up actions such as connecting medical staff, providing medical guidance, and responding to emergencies.
To achieve this, LG CNS plans to utilize "Exaone," developed by LG AI Research, to build a lightweight large language model (sLLM) specialized for healthcare, and implement a big data platform that collects and manages medical, genetic, and lifestyle data.
The two companies are also considering expanding the Connected Healthcare Service globally by leveraging Cha Bio Group's overseas hospital network. They are exploring the potential to expand into related industries in the future, based on the data and experience accumulated during platform operations.
An LG CNS representative stated, "We will strengthen our competitiveness in digital healthcare platforms through cooperation with Cha Bio Group," adding, "We aim to establish ourselves as a technology partner leading AI and data-driven innovation in healthcare."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
